Stoke Therapeutics (STOK) Invested Capital (2022 - 2025)
Historic Invested Capital for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $308.1 million.
- Stoke Therapeutics' Invested Capital rose 3273.92% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 3273.92%. This contributed to the annual value of $229.0 million for FY2024, which is 4352.83% up from last year.
- According to the latest figures from Q3 2025, Stoke Therapeutics' Invested Capital is $308.1 million, which was up 3273.92% from $334.9 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Invested Capital peaked at $350.1 million during Q1 2025, and registered a low of $140.3 million during Q1 2024.
- In the last 4 years, Stoke Therapeutics' Invested Capital had a median value of $224.3 million in 2022 and averaged $228.5 million.
- In the last 5 years, Stoke Therapeutics' Invested Capital crashed by 3436.5% in 2024 and then surged by 14944.35% in 2025.
- Stoke Therapeutics' Invested Capital (Quarter) stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 34.53% to $308.1 million in 2025.
- Its last three reported values are $308.1 million in Q3 2025, $334.9 million for Q2 2025, and $350.1 million during Q1 2025.